Cara Therapeutics, Inc. (NASDAQ:CARA) VP Frederique Ph.D. Menzaghi sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, July 14th. The stock was sold at an average price of $15.00, for a total value of $45,000.00. Following the completion of the sale, the vice president now owns 120,000 shares of the company’s stock, valued at approximately $1,800,000. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Cara Therapeutics, Inc. (CARA) traded down 2.39% during trading on Friday, hitting $15.09. The company had a trading volume of 344,015 shares. Cara Therapeutics, Inc. has a one year low of $4.97 and a one year high of $28.50. The company’s market capitalization is $490.53 million. The stock has a 50-day moving average of $17.60 and a 200 day moving average of $16.09.

Cara Therapeutics (NASDAQ:CARA) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by $0.08. The company had revenue of $0.91 million during the quarter, compared to analyst estimates of $0.11 million. The company’s revenue for the quarter was up 12900.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.39) EPS. Equities analysts forecast that Cara Therapeutics, Inc. will post ($2.44) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/07/21/cara-therapeutics-inc-nasdaqcara-vp-frederique-ph-d-menzaghi-sells-3000-shares.html.

Large investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new stake in Cara Therapeutics during the first quarter valued at $124,000. UBS Group AG boosted its stake in Cara Therapeutics by 16.9% in the first quarter. UBS Group AG now owns 10,544 shares of the biopharmaceutical company’s stock valued at $194,000 after buying an additional 1,528 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its stake in Cara Therapeutics by 0.5% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 11,824 shares of the biopharmaceutical company’s stock valued at $217,000 after buying an additional 60 shares during the last quarter. American International Group Inc. boosted its stake in Cara Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 12,937 shares of the biopharmaceutical company’s stock valued at $238,000 after buying an additional 857 shares during the last quarter. Finally, Two Sigma Securities LLC acquired a new stake in Cara Therapeutics during the first quarter valued at $252,000. Hedge funds and other institutional investors own 52.91% of the company’s stock.

A number of analysts have commented on the company. Janney Montgomery Scott reiterated a “buy” rating and issued a $22.00 price objective on shares of Cara Therapeutics in a research report on Wednesday, June 28th. Vetr upgraded Cara Therapeutics from a “hold” rating to a “buy” rating and set a $27.58 price objective for the company in a research report on Wednesday, June 28th. Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 price objective (down previously from $24.00) on shares of Cara Therapeutics in a research report on Friday, June 30th. Laidlaw reduced their price objective on Cara Therapeutics from $35.00 to $30.00 and set a “buy” rating for the company in a research report on Friday, June 30th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price objective on shares of Cara Therapeutics in a research report on Wednesday, June 21st. Four equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Cara Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $25.68.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Receive News & Stock Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related stocks with our FREE daily email newsletter.